Research from The Shiley Center for Orthopaedic Research and Education at Scripps Clinic could change how patients are treated to prevent blood clots after joint replacement surgery. A study recently published as the lead article in the Journal of Bone and Joint Surgery determined that after lower extremity joint replacement surgery a mobile compression device was just as effective as blood thinners in preventing deep vein thrombosis (DVT), but without negative side effects including bleeding complications.
In collaboration with an international team, researchers at Karolinska Institutet in Sweden have developed an antibody, 3F7, which blocks a protein that is active in the coagulation system factor XII. Inhibition of factor XII makes it possible to prevent thrombosis in blood vessels without increasing the risk of bleeding in clinical settings.
CeloNova has announced the US FDA 510(k) clearance expanding the indication for Embozene microspheres to include the treatment of uterine fibroids.
The European Congress of Radiology (ECR), the annual meeting of the European Society of Radiology (ESR) was held 6–10 March, Vienna, Austria.
A retrospective study reports that individuals who underwent embolization of the left gastric artery for gastrointestinal bleeding experienced a 7.9% decrease in body weight, three months after the procedure. Could embolization of the left gastric artery be used in the treatment of obesity?
BSD Medical has reported continued sales momentum by Terumo on the distribution of the MicroThermX Microwave Ablation system. BSD’s exclusive agreement with Terumo covers distribution of the MicroThermX in more than 100 countries, including Europe, Western Asia and Africa.
Cordis has announced receiving the CE mark for its Renlane renal denervation system for the treatment of patients with resistant hypertension and has completed the first successful cases in Europe.
Cordis Corporation announced that it has entered into an agreement with TriReme Medical that grants the company exclusive distribution rights for the Chocolate percutaneous transluminal angioplasty (PTA) balloon catheter.
Endologix has announced the Journal of Vascular Surgery s (JVS) e-publication of the data from the first prospective, multicentre, randomised clinical trial of a totally percutaneous approach (PEVAR) to endovascular abdominal aortic aneurysm repair (EVAR).
Results from the RELINE trial show that the Viabahn covered stent (Gore) conferred significantly better protection against target lesion revascularisation and had a significantly higher primary patency than percutaneous transluminal angioplasty.
The outcomes from our study on the efficacy and safety of percutaneous cryoablation, published recently in CardioVascular and Interventional Radiology, are the result of the most rigorous investigation on the subject to-date. These exceptional numbers (97%, five-year oncologic efficacy and 6% complication rate) however, are a double-edged sword. On one hand, they approach those of the gold standard, on the other, we must prove they are widely reproducible, writes Christos Georgiades
Deep vein thrombosis (DVT) often brings with it the risk of post-thrombotic syndrome (PTS), an under-recognized but serious complication that often causes long-term disability for patients. During March s DVT Awareness Month, the Society of Interventional Radiology wants to help patients and family members to better understand the long-term risks of DVT.
First Ten Patients Enrolled in U.S. Clinical Study that is Evaluating Treatment of Iliofemoral Venous Outflow Obstruction
Sapheon has announced that it has submitted the second module of the pre-market approval (PMA) application for the VenaSeal Sapheon Closure System to the US Food and Drug Administration (FDA). According to the company, the submission, which was completed on 18 December 2013, “represents steady progress on the modular PMA application for VenaSeal, a minimally invasive, single use kit intended for the treatment of venous reflux disease”. The first module, submitted in September 2013, was reviewed by the FDA and accepted without deficiencies within a single review cycle.
Argon Medical Devices announced that it has received clearance from the US Food and Drug Administration to begin marketing the Option Elite retrievable inferior vena cava filter with a new over-the-wire delivery technique on 16 January 2013.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos